Information Provided By:
Fly News Breaks for December 8, 2016
BIIB
Dec 8, 2016 | 15:47 EDT
Bernstein cautions that Biogen's Alzheimer's disease trial data had a large discontinuation between the double blind stage and the open label and thus, results should be interpreted with caution.